Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
BACKGROUND
Fampridine (4-aminopyridine) is a potassium channel blocker that has been evaluated as a treatment for patients with spinal cord injury and multiple sclerosis.


OBJECTIVE
The purpose of this study was to determine the pharmacokinetics of a single dose of an orally administered solution of (14)C-labeled fampridine in healthy volunteers.


METHODS
In this open-label, single-dose study conducted in an inpatient setting, healthy adult men were administered an oral solution containing 15 mg of (14)C-labeled fampridine (100 microCi) in a fasted state. In addition to blood sampling for analysis of plasma (14)C-radioactivity at prescribed intervals over 7 days, all urine and feces were collected for analysis of drug recovery and disposition. Urine samples were also analyzed for metabolic profiling. Plasma pharmacokinetic parameters of the (14)C-radiolabeled drug were determined using standard liquid-scintillation techniques. Recovery was calculated to provide the total amount of radioactivity excreted as a proportion of the original dose. Nonhydrolyzed and hydrolyzed urine extracts were analyzed for radioactivity and metabolites using reverse-phase, isocratic high-performance liquid chromatography with spectrophotometric and radioactive detection. Tolerability was assessed through evaluation of vital signs, hematologic and other laboratory parameters, and electrocardiography.


RESULTS
The 4 white male subjects had a mean (SD) age of 21 (2) years. No clinically significant abnormalities in vital signs, clinical chemistry, hematology, urinalysis, or electrocardiography were observed either before or during the study. Peak plasma radioactivity was reached at 1 hour after dosing, with a median concentration of 72.9 ng x mL(-1). There was complete disappearance of radioactivity by 24 hours (limit of quantitation, 400 disintegrations/min per peak), and the calculated median t(1/2) was 3.14 hours. Total cumulative recovery of (14)C-radioactivity was 96.36%, with only 0.51% of drug recovered in feces. On chromatography, 2 metabolites accounted for a low proportion of total urinary radioactivity (3% and 6% of total radioactivity in the interval from 0 to 4 hours after dosing; 17% and 9% in the interval from 8 to 12 hours after dosing). Three subjects reported mild and transient dizziness occurring 1 half-hour after dosing; this was considered possibly related to the study drug.


CONCLUSIONS
Fampridine administered as an oral solution was rapidly absorbed and was nearly completely and rapidly eliminated as unchanged drug via urinary excretion, suggesting that it is unlikely to undergo substantial metabolic transformation.
Blight
Andrew R
AR
Acorda Therapeutics, Hawthorne, New York, USA.
Henney
Herbert R
HR
D015761:4-Aminopyridine / Q000009:adverse effects / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000293:Adolescent; D002250:Carbon Radioisotopes; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004244:Dizziness / Q000139:chemically induced; D006207:Half-Life; D006801:Humans; D008297:Male; D019999:Pharmaceutical Solutions; D026902:Potassium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics*; D012588:Scintillation Counting / Q000379:methods; D055815:Young Adult
D002250:Carbon Radioisotopes; D019999:Pharmaceutical Solutions; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine